drugset / Trial / NCT01692756

Early Treatment for Acute ACL Tear

NCT01692756

Phase 2 Completed 49 enrolled Cale Jacobs Vanderbilt University · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This research study is the first of its kind and will allow health care professionals and researchers to answer many questions about the reasons why anterior cruciate ligament (ACL) injury leads to knee pain and disability and osteoarthritis. We also hope that this study will be the beginning of new, more powerful and safer drugs to help patients with ACL injuries heal sooner and return to sports or daily activities pain free. Study participants will be recruited from the University of Kentucky and Vanderbilt University. The purpose of this research is to gather information on how safe and effective Kenalog® is in alleviating knee pain following ACL rupture.

Timeline

Start
2013-03
Primary completion
2017-02-05
Completion
2017-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified 40 mg

Indications

No indication recorded.